According to ClinicalTrials.gov, there is currently one registered trial (NCT02729493) recruiting patients with relapsed or refractory liver cancer for infusion of their own T cells that have been genetically modified to express a CAR targeting EpCAM-positive tumor cells. The gene discussed is EPCAM; the disease is neoplasm.